BioPharma Resources

Drug Trial Radar · NCT06552169

REgulatory T Cell Therapy to Achieve Immunosuppression REduction

The RETIRE Trial: A Randomized Phase 2 Trial of Adoptive Therapy With Treg Adoptive Cell Transfer (TRACT) To Prevent Rejection in Living Donor Kidney Transplant Recipients

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

34

Planned (sponsor's estimate)

Start

Jun 13, 2025

Primary completion

Dec 2027

Study completion Dec 2031

Sponsor

Lead sponsor
Singulera Therapeutics Inc.Industry
Sponsor type
Industry
Collaborators
Taiwan Bio Therapeutics Inc.
First posted
Aug 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this multi-national, multi-center, open-label, randomized Phase 2 trial is to determine the safety and efficacy of administering expanded regulatory T cells (TRK-001) to prevent allograft rejection in living donor renal transplant recipients. Enrolled subjects will be randomized to one of 2 study arms: Arm 1 subjects will receive standard of care immunosuppression Arm 2 subjects will receive initial standard of care (SOC) immunosuppression and a single infusion of TRK-001. Three months after the transplant, Arm 2 subjects may be able to begin reducing their immunosuppression medication to a 1-drug regimen. The primary outcome measures of trial are to evaluate several components indicating immunologic problems with the transplanted organ at 1-year post-transplant and to evaluate the ability for the study subjects given TRK-001 to wean to a 1-drug immunosuppression regimen. All enrolled subjects will be followed for 5 years post-transplant.

Conditions

  • Kidney Transplantation

Interventions

  • Arm 1: SOC (mTOR + CNI)Drug

    Subjects randomized to Arm 1 will remain on standard dual-immunosuppression therapy (CNI and mTOR) throughout the trial.

  • Arm 2A: TRACT/MONO mTORBiological

    All subjects will be prescribed standard of care (SOC) immunosuppressive agents. Subjects randomized to Arm 2 will be maintained on the prescribed SOC immunosuppression (tacrolimus + sirolimus or everolimus) and have a single intravenous infusion of autologous, expanded Tregs (TRK-001) at Day +53 to +67 post-transplant. At Month 3 post-transplant, Arm 2 subjects will be further randomized to receive either: * Arm 2A: mTOR monotherapy or * Arm 2B: CNI monotherapy. These subjects will transition to the assigned 1-drug immunosuppression regimen beginning at Month 3 post-transplant. Weaning must be completed by 12 months post-transplant. Subjects in Arm 2 will undergo leukapheresis to collect peripheral blood mononuclear cells required for the cellular product.

  • Arm 2B: TRACT/MONO CNIBiological

    All subjects will be prescribed standard of care (SOC) immunosuppressive agents. Subjects randomized to Arm 2 will be maintained on the prescribed SOC immunosuppression (tacrolimus + sirolimus or everolimus) and have a single intravenous infusion of autologous, expanded Tregs (TRK-001) at Day +53 to +67 post-transplant. At Month 3 post-transplant, Arm 2 subjects will be further randomized to receive either: * Arm 2A: mTOR monotherapy or * Arm 2B: CNI monotherapy. These subjects will transition to the assigned 1-drug immunosuppression regimen beginning at Month 3 post-transplant. Weaning must be completed by 12 months post-transplant. Subjects in Arm 2 will undergo leukapheresis to collect peripheral blood mononuclear cells required for the cellular product.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Development of de novo donor-specific antibodiesTime frame: Month 12 Post-transplant
  2. Biopsy-proven acute rejectionTime frame: Month 12 Post-transplant
  3. Biopsy-proven subclinical rejectionTime frame: Month 12 Post-transplant
  4. Development of significant (2+) interstitial fibrosis/tubular atrophyTime frame: Month 12 Post-transplant
  5. Successful taper to monotherapy (Arm 2)Time frame: Month 12 Post-transplant

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Mayo Clinic in Arizona

    Phoenix, Arizona · Recruiting

  • Northwestern Memorial Hospital

    Chicago, Illinois · Recruiting

  • Mayo Clinic in Minnesota

    Rochester, Minnesota · Recruiting

  • Taichung Veterans General Hospital

    Taichung, Taiwan · Recruiting

  • National Cheng Kung University Hospital

    Tainan, Taiwan · Recruiting

  • National Taiwan University Hospital

    Taipei, Taiwan · Recruiting

  • Chang Gung Medical Foundation Hospital

    Taoyuan, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.